# ALX Oncology

Source: https://onco.cc/companies/alx-oncology/  
OnCo record `alx-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ALX Oncology is a Californian biotechnology company developing evorpacept, a CD47-blocking fusion protein designed to remove the 'do not eat me' signal so that antibodies such as trastuzumab can recruit macrophages against HER2-positive gastric cancer.

## Summary

ALX Oncology, based in South San Francisco, develops evorpacept (ALX148), an engineered SIRP-alpha fusion protein that blocks CD47 without the red-cell toxicity of earlier CD47 antibodies, so it can be combined with tumour-targeting antibodies to enhance macrophage attack. Its lead trial ASPEN-06 tests evorpacept with trastuzumab, ramucirumab and paclitaxel in previously treated HER2-positive gastric cancer, and the company is studying the drug in other antibody combinations. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: ALX Oncology Holdings
- Tags: ctgov-sponsor
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://alxoncology.com/

## Sources

- Official website: https://alxoncology.com/
- ClinicalTrials.gov: trials led by ALX Oncology: https://clinicaltrials.gov/search?lead=ALX%20Oncology

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- targets: [CD47](https://onco.cc/targets/cd47/)
- drugs: [Evorpacept](https://onco.cc/drugs/evorpacept/)
- trials: [A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)](https://onco.cc/trials/aspen-06/), [ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer](https://onco.cc/trials/nct07007559/), [Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)](https://onco.cc/trials/nct04675333/), [Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)](https://onco.cc/trials/nct04675294/), [PRE-ISPY Phase I/II Oncology Platform Program](https://onco.cc/trials/nct05868226/)

---
JSON: https://onco.cc/api/v1/entities/alx-oncology.json